Dose-dependent transitions in mechanisms of toxicity
Scientists and decision makers from all sectors agree that risk assessments should be based on the best available science. Several years ago, the Health and Environmental Sciences Institute (HESI), a global branch of the International Life Sciences Institute (ILSI), identified the need for better sc...
Gespeichert in:
Veröffentlicht in: | Toxicology and applied pharmacology 2004-12, Vol.201 (3), p.203-225 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 225 |
---|---|
container_issue | 3 |
container_start_page | 203 |
container_title | Toxicology and applied pharmacology |
container_volume | 201 |
creator | Slikker, William Andersen, Melvin E. Bogdanffy, Matthew S. Bus, James S. Cohen, Steven D. Conolly, Rory B. David, Raymond M. Doerrer, Nancy G. Dorman, David C. Gaylor, David W. Hattis, Dale Rogers, John M. Woodrow Setzer, R. Swenberg, James A. Wallace, Kendall |
description | Scientists and decision makers from all sectors agree that risk assessments should be based on the best available science. Several years ago, the Health and Environmental Sciences Institute (HESI), a global branch of the International Life Sciences Institute (ILSI), identified the need for better scientific understanding of dose-dependent transitions in mechanisms of toxicity as one avenue by which the best and latest science can be integrated into the decision making process. In July 2001, the HESI Project Committee on Dose-Dependent Transitions in Mechanisms of Toxicity established a group of academic, government, and industry scientists to engage in active technical discourse on the issue of dose-dependent transitions in mechanisms of toxicity. Over the next 18 months, case studies were examined. These case studies included acetaminophen, butadiene, ethylene glycol, formaldehyde, manganese, methylene chloride, the peroxisome proliferator-activated receptor, progesterone/hydroxyflutamide, propylene oxide, vinyl acetate, vinyl chloride, vinylidene chloride, and zinc (Slikker, W., Jr., Andersen, M.E., Bogdanffy, M.S., Bus, J.S., Cohen, S.D., Conolly, R.B., David, R.M., Doerrer, N.G., Dorman, D.C., Gaylor, D.W., Hattis, D., Rogers, J.M., Setzer, R.W., Swenberg, J.A., Wallace, K., 2004. Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol. Appl. Pharmacol. 201(3), 226–294 (this issue)). The HESI Project Committee sponsored two technical workshops in 2003. The first of these workshops took place on February 12–13, 2003, and was co-sponsored by the Agency for Toxic Substances and Disease Registry, the American Chemistry Council, the National Institute of Environmental Health Sciences, the Society of Toxicology, and the U.S. Environmental Protection Agency. Additional support was provided by Health Canada. Invited experts from government, academia, and industry provided scientific perspectives and recommendations at the workshop. The purpose of the workshop was to examine approaches to dose–response analysis, learn from the case study examples, and gather feedback from invited participants on the impact of dose-dependent transitions on the risk assessment process. The second forum consisted of a workshop in March 2003 at the Society of Toxicology Annual Meeting in Salt Lake City, UT. This paper addresses the issues discussed at both workshops, and presents the consensus conclusions drawn by expert participants. |
doi_str_mv | 10.1016/j.taap.2004.06.019 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17785441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041008X04003187</els_id><sourcerecordid>17785441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-789e264081016788de3c6683290467370356415a795432016aba4fc493b862e93</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EoqXwAgwoC2wJx7HjOBILKlepEgtIbJbrnAhXuRG7iL49jhqpG9MZzvefy0fIJYWEAhW3m8Rr3ScpAE9AJECLIzKnUIgYGGPHZB4aNAaQnzNy5twGAArO6SmZ0SyTqeDZnPCHzmFcYo9tia2P_KBbZ73tWhfZNmrQfOnWusZFXRX57tca63fn5KTStcOLqS7Ix9Pj-_IlXr09vy7vV7HhlPk4lwWGLSDHa3MpS2RGCMnSArjIWQ4sE5xmOi8yztLA6LXmleEFW0uRYsEW5GY_tx-67y06rxrrDNa1brHbOkXzXGbhowCme9AMnXMDVqofbKOHnaKgxu1qo0ZXanSlQKjgKoSupunbdYPlITLJCcD1BGhndF0FNca6AyeYCLIhcHd7DoOLH4uDcsZia7C0Axqvys7-d8cftdqE4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17785441</pqid></control><display><type>article</type><title>Dose-dependent transitions in mechanisms of toxicity</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Slikker, William ; Andersen, Melvin E. ; Bogdanffy, Matthew S. ; Bus, James S. ; Cohen, Steven D. ; Conolly, Rory B. ; David, Raymond M. ; Doerrer, Nancy G. ; Dorman, David C. ; Gaylor, David W. ; Hattis, Dale ; Rogers, John M. ; Woodrow Setzer, R. ; Swenberg, James A. ; Wallace, Kendall</creator><creatorcontrib>Slikker, William ; Andersen, Melvin E. ; Bogdanffy, Matthew S. ; Bus, James S. ; Cohen, Steven D. ; Conolly, Rory B. ; David, Raymond M. ; Doerrer, Nancy G. ; Dorman, David C. ; Gaylor, David W. ; Hattis, Dale ; Rogers, John M. ; Woodrow Setzer, R. ; Swenberg, James A. ; Wallace, Kendall</creatorcontrib><description>Scientists and decision makers from all sectors agree that risk assessments should be based on the best available science. Several years ago, the Health and Environmental Sciences Institute (HESI), a global branch of the International Life Sciences Institute (ILSI), identified the need for better scientific understanding of dose-dependent transitions in mechanisms of toxicity as one avenue by which the best and latest science can be integrated into the decision making process. In July 2001, the HESI Project Committee on Dose-Dependent Transitions in Mechanisms of Toxicity established a group of academic, government, and industry scientists to engage in active technical discourse on the issue of dose-dependent transitions in mechanisms of toxicity. Over the next 18 months, case studies were examined. These case studies included acetaminophen, butadiene, ethylene glycol, formaldehyde, manganese, methylene chloride, the peroxisome proliferator-activated receptor, progesterone/hydroxyflutamide, propylene oxide, vinyl acetate, vinyl chloride, vinylidene chloride, and zinc (Slikker, W., Jr., Andersen, M.E., Bogdanffy, M.S., Bus, J.S., Cohen, S.D., Conolly, R.B., David, R.M., Doerrer, N.G., Dorman, D.C., Gaylor, D.W., Hattis, D., Rogers, J.M., Setzer, R.W., Swenberg, J.A., Wallace, K., 2004. Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol. Appl. Pharmacol. 201(3), 226–294 (this issue)). The HESI Project Committee sponsored two technical workshops in 2003. The first of these workshops took place on February 12–13, 2003, and was co-sponsored by the Agency for Toxic Substances and Disease Registry, the American Chemistry Council, the National Institute of Environmental Health Sciences, the Society of Toxicology, and the U.S. Environmental Protection Agency. Additional support was provided by Health Canada. Invited experts from government, academia, and industry provided scientific perspectives and recommendations at the workshop. The purpose of the workshop was to examine approaches to dose–response analysis, learn from the case study examples, and gather feedback from invited participants on the impact of dose-dependent transitions on the risk assessment process. The second forum consisted of a workshop in March 2003 at the Society of Toxicology Annual Meeting in Salt Lake City, UT. This paper addresses the issues discussed at both workshops, and presents the consensus conclusions drawn by expert participants.</description><identifier>ISSN: 0041-008X</identifier><identifier>EISSN: 1096-0333</identifier><identifier>DOI: 10.1016/j.taap.2004.06.019</identifier><identifier>PMID: 15582645</identifier><identifier>CODEN: TXAPA9</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Animals ; Biological and medical sciences ; DNA Adducts - drug effects ; Dose-dependent transitions ; Dose-Response Relationship, Drug ; Dose–response ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Inactivation, Metabolic ; Mechanisms of toxicity ; Medical sciences ; Research Design ; Risk Assessment ; Toxicology</subject><ispartof>Toxicology and applied pharmacology, 2004-12, Vol.201 (3), p.203-225</ispartof><rights>2004</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-789e264081016788de3c6683290467370356415a795432016aba4fc493b862e93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.taap.2004.06.019$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16360960$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15582645$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Slikker, William</creatorcontrib><creatorcontrib>Andersen, Melvin E.</creatorcontrib><creatorcontrib>Bogdanffy, Matthew S.</creatorcontrib><creatorcontrib>Bus, James S.</creatorcontrib><creatorcontrib>Cohen, Steven D.</creatorcontrib><creatorcontrib>Conolly, Rory B.</creatorcontrib><creatorcontrib>David, Raymond M.</creatorcontrib><creatorcontrib>Doerrer, Nancy G.</creatorcontrib><creatorcontrib>Dorman, David C.</creatorcontrib><creatorcontrib>Gaylor, David W.</creatorcontrib><creatorcontrib>Hattis, Dale</creatorcontrib><creatorcontrib>Rogers, John M.</creatorcontrib><creatorcontrib>Woodrow Setzer, R.</creatorcontrib><creatorcontrib>Swenberg, James A.</creatorcontrib><creatorcontrib>Wallace, Kendall</creatorcontrib><title>Dose-dependent transitions in mechanisms of toxicity</title><title>Toxicology and applied pharmacology</title><addtitle>Toxicol Appl Pharmacol</addtitle><description>Scientists and decision makers from all sectors agree that risk assessments should be based on the best available science. Several years ago, the Health and Environmental Sciences Institute (HESI), a global branch of the International Life Sciences Institute (ILSI), identified the need for better scientific understanding of dose-dependent transitions in mechanisms of toxicity as one avenue by which the best and latest science can be integrated into the decision making process. In July 2001, the HESI Project Committee on Dose-Dependent Transitions in Mechanisms of Toxicity established a group of academic, government, and industry scientists to engage in active technical discourse on the issue of dose-dependent transitions in mechanisms of toxicity. Over the next 18 months, case studies were examined. These case studies included acetaminophen, butadiene, ethylene glycol, formaldehyde, manganese, methylene chloride, the peroxisome proliferator-activated receptor, progesterone/hydroxyflutamide, propylene oxide, vinyl acetate, vinyl chloride, vinylidene chloride, and zinc (Slikker, W., Jr., Andersen, M.E., Bogdanffy, M.S., Bus, J.S., Cohen, S.D., Conolly, R.B., David, R.M., Doerrer, N.G., Dorman, D.C., Gaylor, D.W., Hattis, D., Rogers, J.M., Setzer, R.W., Swenberg, J.A., Wallace, K., 2004. Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol. Appl. Pharmacol. 201(3), 226–294 (this issue)). The HESI Project Committee sponsored two technical workshops in 2003. The first of these workshops took place on February 12–13, 2003, and was co-sponsored by the Agency for Toxic Substances and Disease Registry, the American Chemistry Council, the National Institute of Environmental Health Sciences, the Society of Toxicology, and the U.S. Environmental Protection Agency. Additional support was provided by Health Canada. Invited experts from government, academia, and industry provided scientific perspectives and recommendations at the workshop. The purpose of the workshop was to examine approaches to dose–response analysis, learn from the case study examples, and gather feedback from invited participants on the impact of dose-dependent transitions on the risk assessment process. The second forum consisted of a workshop in March 2003 at the Society of Toxicology Annual Meeting in Salt Lake City, UT. This paper addresses the issues discussed at both workshops, and presents the consensus conclusions drawn by expert participants.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>DNA Adducts - drug effects</subject><subject>Dose-dependent transitions</subject><subject>Dose-Response Relationship, Drug</subject><subject>Dose–response</subject><subject>Drug-Related Side Effects and Adverse Reactions</subject><subject>Humans</subject><subject>Inactivation, Metabolic</subject><subject>Mechanisms of toxicity</subject><subject>Medical sciences</subject><subject>Research Design</subject><subject>Risk Assessment</subject><subject>Toxicology</subject><issn>0041-008X</issn><issn>1096-0333</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtOwzAUhi0EoqXwAgwoC2wJx7HjOBILKlepEgtIbJbrnAhXuRG7iL49jhqpG9MZzvefy0fIJYWEAhW3m8Rr3ScpAE9AJECLIzKnUIgYGGPHZB4aNAaQnzNy5twGAArO6SmZ0SyTqeDZnPCHzmFcYo9tia2P_KBbZ73tWhfZNmrQfOnWusZFXRX57tca63fn5KTStcOLqS7Ix9Pj-_IlXr09vy7vV7HhlPk4lwWGLSDHa3MpS2RGCMnSArjIWQ4sE5xmOi8yztLA6LXmleEFW0uRYsEW5GY_tx-67y06rxrrDNa1brHbOkXzXGbhowCme9AMnXMDVqofbKOHnaKgxu1qo0ZXanSlQKjgKoSupunbdYPlITLJCcD1BGhndF0FNca6AyeYCLIhcHd7DoOLH4uDcsZia7C0Axqvys7-d8cftdqE4w</recordid><startdate>20041215</startdate><enddate>20041215</enddate><creator>Slikker, William</creator><creator>Andersen, Melvin E.</creator><creator>Bogdanffy, Matthew S.</creator><creator>Bus, James S.</creator><creator>Cohen, Steven D.</creator><creator>Conolly, Rory B.</creator><creator>David, Raymond M.</creator><creator>Doerrer, Nancy G.</creator><creator>Dorman, David C.</creator><creator>Gaylor, David W.</creator><creator>Hattis, Dale</creator><creator>Rogers, John M.</creator><creator>Woodrow Setzer, R.</creator><creator>Swenberg, James A.</creator><creator>Wallace, Kendall</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20041215</creationdate><title>Dose-dependent transitions in mechanisms of toxicity</title><author>Slikker, William ; Andersen, Melvin E. ; Bogdanffy, Matthew S. ; Bus, James S. ; Cohen, Steven D. ; Conolly, Rory B. ; David, Raymond M. ; Doerrer, Nancy G. ; Dorman, David C. ; Gaylor, David W. ; Hattis, Dale ; Rogers, John M. ; Woodrow Setzer, R. ; Swenberg, James A. ; Wallace, Kendall</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-789e264081016788de3c6683290467370356415a795432016aba4fc493b862e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>DNA Adducts - drug effects</topic><topic>Dose-dependent transitions</topic><topic>Dose-Response Relationship, Drug</topic><topic>Dose–response</topic><topic>Drug-Related Side Effects and Adverse Reactions</topic><topic>Humans</topic><topic>Inactivation, Metabolic</topic><topic>Mechanisms of toxicity</topic><topic>Medical sciences</topic><topic>Research Design</topic><topic>Risk Assessment</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Slikker, William</creatorcontrib><creatorcontrib>Andersen, Melvin E.</creatorcontrib><creatorcontrib>Bogdanffy, Matthew S.</creatorcontrib><creatorcontrib>Bus, James S.</creatorcontrib><creatorcontrib>Cohen, Steven D.</creatorcontrib><creatorcontrib>Conolly, Rory B.</creatorcontrib><creatorcontrib>David, Raymond M.</creatorcontrib><creatorcontrib>Doerrer, Nancy G.</creatorcontrib><creatorcontrib>Dorman, David C.</creatorcontrib><creatorcontrib>Gaylor, David W.</creatorcontrib><creatorcontrib>Hattis, Dale</creatorcontrib><creatorcontrib>Rogers, John M.</creatorcontrib><creatorcontrib>Woodrow Setzer, R.</creatorcontrib><creatorcontrib>Swenberg, James A.</creatorcontrib><creatorcontrib>Wallace, Kendall</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Toxicology and applied pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Slikker, William</au><au>Andersen, Melvin E.</au><au>Bogdanffy, Matthew S.</au><au>Bus, James S.</au><au>Cohen, Steven D.</au><au>Conolly, Rory B.</au><au>David, Raymond M.</au><au>Doerrer, Nancy G.</au><au>Dorman, David C.</au><au>Gaylor, David W.</au><au>Hattis, Dale</au><au>Rogers, John M.</au><au>Woodrow Setzer, R.</au><au>Swenberg, James A.</au><au>Wallace, Kendall</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dose-dependent transitions in mechanisms of toxicity</atitle><jtitle>Toxicology and applied pharmacology</jtitle><addtitle>Toxicol Appl Pharmacol</addtitle><date>2004-12-15</date><risdate>2004</risdate><volume>201</volume><issue>3</issue><spage>203</spage><epage>225</epage><pages>203-225</pages><issn>0041-008X</issn><eissn>1096-0333</eissn><coden>TXAPA9</coden><abstract>Scientists and decision makers from all sectors agree that risk assessments should be based on the best available science. Several years ago, the Health and Environmental Sciences Institute (HESI), a global branch of the International Life Sciences Institute (ILSI), identified the need for better scientific understanding of dose-dependent transitions in mechanisms of toxicity as one avenue by which the best and latest science can be integrated into the decision making process. In July 2001, the HESI Project Committee on Dose-Dependent Transitions in Mechanisms of Toxicity established a group of academic, government, and industry scientists to engage in active technical discourse on the issue of dose-dependent transitions in mechanisms of toxicity. Over the next 18 months, case studies were examined. These case studies included acetaminophen, butadiene, ethylene glycol, formaldehyde, manganese, methylene chloride, the peroxisome proliferator-activated receptor, progesterone/hydroxyflutamide, propylene oxide, vinyl acetate, vinyl chloride, vinylidene chloride, and zinc (Slikker, W., Jr., Andersen, M.E., Bogdanffy, M.S., Bus, J.S., Cohen, S.D., Conolly, R.B., David, R.M., Doerrer, N.G., Dorman, D.C., Gaylor, D.W., Hattis, D., Rogers, J.M., Setzer, R.W., Swenberg, J.A., Wallace, K., 2004. Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol. Appl. Pharmacol. 201(3), 226–294 (this issue)). The HESI Project Committee sponsored two technical workshops in 2003. The first of these workshops took place on February 12–13, 2003, and was co-sponsored by the Agency for Toxic Substances and Disease Registry, the American Chemistry Council, the National Institute of Environmental Health Sciences, the Society of Toxicology, and the U.S. Environmental Protection Agency. Additional support was provided by Health Canada. Invited experts from government, academia, and industry provided scientific perspectives and recommendations at the workshop. The purpose of the workshop was to examine approaches to dose–response analysis, learn from the case study examples, and gather feedback from invited participants on the impact of dose-dependent transitions on the risk assessment process. The second forum consisted of a workshop in March 2003 at the Society of Toxicology Annual Meeting in Salt Lake City, UT. This paper addresses the issues discussed at both workshops, and presents the consensus conclusions drawn by expert participants.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>15582645</pmid><doi>10.1016/j.taap.2004.06.019</doi><tpages>23</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-008X |
ispartof | Toxicology and applied pharmacology, 2004-12, Vol.201 (3), p.203-225 |
issn | 0041-008X 1096-0333 |
language | eng |
recordid | cdi_proquest_miscellaneous_17785441 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Animals Biological and medical sciences DNA Adducts - drug effects Dose-dependent transitions Dose-Response Relationship, Drug Dose–response Drug-Related Side Effects and Adverse Reactions Humans Inactivation, Metabolic Mechanisms of toxicity Medical sciences Research Design Risk Assessment Toxicology |
title | Dose-dependent transitions in mechanisms of toxicity |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T08%3A49%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dose-dependent%20transitions%20in%20mechanisms%20of%20toxicity&rft.jtitle=Toxicology%20and%20applied%20pharmacology&rft.au=Slikker,%20William&rft.date=2004-12-15&rft.volume=201&rft.issue=3&rft.spage=203&rft.epage=225&rft.pages=203-225&rft.issn=0041-008X&rft.eissn=1096-0333&rft.coden=TXAPA9&rft_id=info:doi/10.1016/j.taap.2004.06.019&rft_dat=%3Cproquest_cross%3E17785441%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17785441&rft_id=info:pmid/15582645&rft_els_id=S0041008X04003187&rfr_iscdi=true |